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Recent epidemiological studies show a reduced Results and discussion
Using both detergent (Triton X-100, Lubrol WX, andprevalence of Alzheimer’s disease (AD) in patients
treated with inhibitors of cholesterol biosynthesis CHAPS) and nondetergent (carbonate) methods [22–24],
we isolated rafts from Chinese hamster ovary (CHO) cells[1, 2]. Moreover, the cholesterol-transport protein,
apolipoprotein E4, and elevated cholesterol are stably expressing Asp2 tagged with tandem c-myc and
hexa histidine epitopes [25]. Following density gradientimportant risk factors for AD [3–5]. Additionally, in
vitro and in vivo studies show that intracellular ultracentrifugation of cell homogenates, it was found that
both detergent and nondetergent methods gave essen-cholesterol levels can modulate the processing of
amyloid precursor protein (APP) to -amyloid [6–11], tially identical results, with clear enrichment of Asp2 in
the light membrane raft fraction (Figure 1, fractions 4–6).the major constituent of senile plaques [12–14].
Cholesterol plays a crucial role in maintaining lipid The 22-kDa raft-associated protein caveolin-1 was used
as a specific marker [16–18]. We did note, however, somerafts in a functional state [15]. Lipid rafts are
cholesterol-enriched membrane microdomains variability between detergents, and, in particular, Triton
X-100 poorly separated known raft proteins from nonraftimplicated in signal transduction, protein
trafficking, and proteolytic processing [15–18]. Since proteins in CHO cells (Figure 1a). Overall, we found
that Lubrol WX gave the most reproducible results withAPP, -amyloid, and the putative -secretase,
presenilin-1 (PS-1), have all been found in lipid rafts respect to conventional raft markers (Figure 1b) and, as
such, used this as the detergent of choice for the remain-[12, 19–21], we hypothesized that the recently
identified -secretase, Asp2 (BACE1) [13], might der of the study. Asp2 isolated from stably transfected
human embryonic kidney (HEK293) and neuronal (SH-also be present in rafts. Here, we report that
recombinant Asp2 expressed in three distinct cell SY5Y) cell lines also migrated with the light membrane
fraction (Figure 1e,f), indicating that the raft associationlines is raft associated. Using both detergent and
nondetergent methods, Asp2 protein and activity of Asp2 was unlikely to be dependent on cell type. Here,
flotillin-1 was used as a raft marker [19], since HEK293were found in a light membrane raft fraction that
also contained other components of the and neuronal cells lack appreciable levels of caveolin-1
[19, 26]. Additionally, the enrichment of Asp2 within lightamyloidogenic pathway. Immunoisolation of
caveolin-containing vesicles indicated that Asp2 was membranes was independent of the epitope tags, as un-
tagged Asp2 also migrated to rafts (see Figure S1 in thepresent in a unique raft population distinct from
caveolae. Finally, depletion of raft cholesterol Supplementary material available with this article online).
abrogated association of Asp2 with the light
membrane fraction. These observations are
In transfected CHO cells, Asp2 appears as two immunore-consistent with the raft localization of APP
active bands that have respective molecular masses (Mr)processing and suggest that the partitioning of Asp2
of 80 kDa and 70 kDa (Figure 1a–d and Figure S2into lipid rafts may underlie the cholesterol
in the Supplementary material). These correspond to thesensitivity of -amyloid production.
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Next, we analyzed the -secretase activity across the Lu-
brol WX gradient fractions. Using a Swedish variant APPPublished: 21 August 2001
peptide as a substrate [28], we found high levels of peptide
Current Biology 2001, 11:1288–1293 cleavage in the raft fractions of Asp2-expressing CHO
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that this cleavage was at the expected -secretase site.
Consistent with previous reports [13], pepstatin inhibited
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Figure 1
Detection of Asp2 in lipid rafts. CHO cells
stably overexpressing Asp2 were grown to
confluency in 175-cm2 flasks and lysed in 2
ml MBS buffer (25 mM MES, 150 mM NaCl
[pH 6.5]) containing either (a) 1% (v/v) Triton
X-100, (b) 1% (w/v) Lubrol WX, (c) 1%
(w/v) CHAPS, or (d) 500 mM sodium
carbonate. These homogenates were then
fractionated on a 5%–35% (w/v)
discontinuous sucrose density gradient as
previously described [22–24]. Fractions (12 
1 ml) were collected from the top of the tube.
Aliquots (25 l) of fractions 2–12 were
analyzed for Asp2 and caveolin by SDS-
PAGE and immunoblotting with monoclonal
anti-myc (clone 9E10, Sigma-Aldrich) and
polyclonal anti-caveolin-1 (C13630,
Transduction Laboratories), respectively.
Lipid rafts (fractions 4–6) floated to the
5%–35% interface and were enriched in
caveolin-1. Flasks (75 cm2) of (e) HEK293 or
(f) SH-SY5Y cells stably overexpressing
Asp2 were lysed in 1% (w/v) Lubrol WX,
fractionated, and analyzed by immunoblotting
with anti-myc and monoclonal anti-flotillin-1
(clone18, Transduction Laboratories). All
molecular weights indicated here and in Figure
3 are in kDa.
this activity weakly (data not shown). Interestingly, al- -secretase activity was also found in the rafts prepared
from untransfected cells (Figure 2a). This indicates thatthough most of the activity detected was directly attribut-
able to the overexpressed Asp2, a low level of endogenous endogenous -secretase may also be localized to rafts.
Figure 2
-secretase activity cofractionates with lipid
rafts. (a) Lubrol WX gradient fractions
obtained from Asp2 transfected (solid square)
and untransfected (open circle) CHO cells
were subjected to peptide cleavage studies
in the presence of 1% (v/v) NP-40, using the
Swedish variant APP peptide
(ISEVNLDAEFRHDK[dnp]G) as before [28].
The chromogenic dnp group on the peptide
was detected by monitoring the absorbance
at 360 nm. The protein concentration across
the gradient fractions was determined
colorimetrically using the Coomassie Plus
protein assay reagent (Pierce & Warriner).
Specific activities were expressed as nmol
substrate cleaved per mg of protein per hr.
Data points represent the mean activity
(SEM) from three separate raft
preparations. (b) A typical reverse phase-
HPLC profile showing the dnp-labeled
substrate and product peaks produced by lipid
rafts isolated from Asp2-transfected CHO
cells. The amino acid sequences of the
peptides as determined by mass
spectrometry are shown.
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Figure 3
Proteins of the amyloidogenic pathway associate with lipid rafts. Asp2- Ab54 [25]. PS-1 NTF was detected using polyclonal antiserum raised
expressing CHO cell rafts were prepared as described in Figure 1 against amino acids 1–20 of PS-1 as described previously [32].
using either (a) detergent (Lubrol WX) or (b) nondetergent (carbonate) Flotillin-1 was detected as described in Figure 1. The free cholesterol
methods and analyzed by SDS-PAGE and immunoblotting. APP concentration in sucrose gradient fractions was determined
was detected using a monoclonal anti-amino-terminal antibody spectrophotometrically by a cholesterol oxidase/peroxidase assay kit
(22C11). The carboxy-terminal fragments of APP generated by  (Boehringer Mannheim). Finally, protein concentrations were
or  cleavage, CTF or CTF, were detected using polyclonal antisera determined as in Figure 2.
We then investigated the distribution of the amyloido- a distinct microdomain within which  cleavage occurs.
Finally, we analyzed the gradient profile of PS-1. Full-genic-related proteins; APP, the - and -secretase-derived
carboxy-terminal fragments of APP (CTF and CTF, length PS-1 is rapidly cleaved within the cell, to produce
an amino-terminal fragment (PS-1 NTF) and a carboxy-respectively), and PS-1, across theCHOLubrolWX gradi-
ents. As expected, the raft fractions consistently contained terminal fragment [21]. Analysis of the profile of PS-1
NTF showed that, as expected [19, 21], it was also concen-5% of the total cellular protein but most of the cellular
cholesterol (Figure 3a). A small proportion of APP cofrac- trated into raft fractions. While broadly similar profiles
were observed using the nondetergent carbonate lysis, ationated with both flotillin-1 and caveolin-1 in the low-
density fractions; however, as reported elsewhere [12, 19], significantly higher proportion of APP localized to the
carbonate raft fractions andCTF floated to the 45%–35%the majority of APP remained in the high-density nonraft
fractions (Figure 3a). Interestingly, we found that most sucrose interface (Figure 3b, fractions 8–10). A more de-
tailed analysis of each isolation procedure will be requiredof the CTF cofractionated with Asp2 in rafts. This im-
plies that intracellular -cleavage may indeed occur in to understand the significance, if any, of these discrepant
profiles.these cholesterol-enrichedmicrodomains [19]. In contrast,
CTF consistently floated to a light membrane fraction
that was relatively poor in cholesterol (Figure 3a, fractions It has been reported previously that endogenous APP
localizes to plasmalemmal caveolae [29]. Caveolae are a6–8). It remains to be seenwhether this fraction represents
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Figure 4
Asp2 is present in a light membrane fraction distinct from caveolae. Double staining of Asp2, APP, or PS-1 with caveolin-1. Asp2 and
(a) Pure caveolae were isolated by immunoprecipitation using anti- APP were detected with the mouse monoclonal antibodies
caveolin polyclonal antiserum (C13630, Transduction Laboratories) described in Figures 1 and 3. PS-1 was detected using the mouse
as described previously [24]. Immunoprecipitated proteins were monoclonal anti-PS-1 NTF. Caveolin-1 was detected using the rabbit
detected by SDS-PAGE and immunoblotting. Caveolin-1 was polyclonal antibody. Bound antibody was visualized using Alexa 488-
detected using monoclonal anti-caveolin-1 (C13620, Transduction conjugated anti-mouse and Alexa 594-conjugated anti-rabbit
Laboratories). PS-1 was detected using mouse monoclonal anti- antibodies (Molecular Probes). Note the lack of colocalization between
PS-1 NTF (clone B-6, Santa Cruz Biotechnology). All other antigens the amyloidogenic proteins and caveolin-1.
were detected using antibodies described in Figures 1 and 3. (b)
subpopulation of lipid rafts described as “small flask- predominantly within the endomembrane system, with
only a small percentage of each protein reaching theshaped invaginations of the plasma membrane that are
characteristically enriched in caveolin-1” [16–18, 21]. plasma membrane [13]. Indeed, using indirect immuno-
fluorescence microscopy, we saw precisely this patternIkezu et al. reported that APP cofractionated with caveo-
lin-1 in three distinct cell lines [29]; however, as pointed of subcellular localization for Asp2, APP, and PS-1, and,
significantly, in each case there was a complete lack ofout recently, the colocalization of proteins in a light mem-
brane fraction is insufficient to prove true caveolar com- colocalization with caveolin-1 (Figure 4b).
partmentalization [24]. Immunoprecipitation of pure ca-
veolae using antibodies against caveolin-1 [24] routinely Cholesterol is an essential component of lipid rafts [15].
Cholesterol depletion either by cholesterol binding agentsisolated between 70% and 100% of the caveolin-1-con-
taining vesicles from our nondetergent raft preparations or inhibitors of cholesterol synthesis [6, 30] can perturb
raft function, possibly by abolishing the association of(Figure 4a). However, and in contrast to Ikezu et al., we
found that APP, CTF, PS-1 NTF, and Asp2 always certain proteins with rafts [17, 18]. Methyl--cyclodextrin
(CD) can selectively and rapidly extract cholesterol fromremained quantitatively in the supernatant (Figure 4a).
The presence of Asp2, APP, and PS-1 in raft fractions the membranes of living cells without affecting their via-
bility [6, 30]. We therefore treated Asp2-expressing CHOdistinct from caveolae is consistent with their observed
subcellular localization; each of these proteins colocalize cells with 5 mM CD for 2 hr, followed by Lubrol WX
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Figure 5
Cholesterol depletion shifts Asp2 out of lipid
rafts. Asp2-overexpressing CHO cells were
grown to confluency in 175-cm2 flasks,
washed in warm PBS, and incubated with (solid
circle) or without (open square) 5 mM methyl-
-cyclodextrin (CD) in serum-free media.
After a 2 hr incubation at 37C, the cells were
lysed in 1% (w/v) Lubrol WX, fractionated,
and processed for (a) cholesterol content and
(b) distribution of Asp2 protein and activity.
Cholesterol levels were determined as in
Figure 3. -secretase activity was
determined as in Figure 2 but was expressed
as percent total activity across the gradient
fractions. Asp2 protein distribution was
determined by immunoblotting with anti-myc.
(c) Total cell lysates, raft (pooled fractions
4–6), and nonraft (pooled fractions 9–12)
fractions were assayed for protein as in Figure
2. Raft (1 g), nonraft (10 g), and total cell
lysates (10 g) of treated and nontreated cells
were immunoblotted for Asp2 using
anti-myc.
extraction. Under these conditions, approximately 65% of conditions, only a small percentage of total cellular APP
is processed via a -secretase-mediated pathway [31].the total raft cholesterol was removed from treated cells
(Figure 5a). Although total raft protein levels were similar However, during periods of high intracellular cholesterol,
it appears that APP is more readily processed by -secre-between treated and untreated cells (157.4  15.8 g
versus 136.2 15.3 g, respectively), a clear shift of Asp2 tase, leading to an increased production of both CTF
and-amyloid [7–11]. It is therefore tempting to speculateimmunoreactive protein from raft to nonraft fractions was
observed in cholesterol-depleted cells (Figure 5b,c and that the confinement of Asp2 into a cholesterol-enriched
lipid raft environment influences its ability to processTable S1 in the Supplementary material). This shift in
Asp2 protein was mirrored by a corresponding shift in APP. One possibility is that altered intracellular choles-
terol levels may alter the relative distribution of Asp2 and/-secretase activity to nonraft fractions (Figure 5b and
Table S1). Equivalent amounts of total Asp2 protein were or APP [6] in rafts, allowing a preferential association
under hypercholesterolemic conditions. Alternatively, therecovered from cholesterol-depleted and nondepleted
cells (Figure 5c), indicating that, under these experimen- ordered lipid environment generated by the presence of
cholesterol in the raft could directly affect Asp2 activity,tal conditions, the steady state levels of Asp2 were unaf-
fected. Finally, the effects of CD were specific, as the perhaps by altering protein conformation [17, 18]. Clearly,
further experiments will be required to fully elucidateaddition of CD in the presence of exogenous cholesterol
[6] did not bring about a shift of Asp2 to a higher density the intriguing relationship between Asp2, cholesterol, and
AD, an approach which may one day lead to novel thera-nonraft fraction (Figure S3 in the Supplementary mate-
rial). Thus, under similar conditions in which -amyloid pies that halt the progression of this debilitating illness.
production has been shown to be inhibited [6], Asp2 disso-
ciates from rafts. Supplementary material
Supplementary material including additional methodological details, fig-
ures showing the raft localization of untagged Asp2, the endoH sensitivityTaken together, these data suggest that Asp2 is compart-
of nonraft Asp2, and the effect of CD in the presence of exogenous
mentalized into cholesterol-enriched, low-buoyant den- cholesterol on Asp2 raft localization is available at http://images.
sity, noncaveolar lipid rafts together with key components cellpress.com/supmat/supmatin.htm.
of the amyloidogenic cascade. The colocalization of sub-
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